Cizzle Biotechnology Holdings PLC (CIZ) Share Price & Analysis

3 Followers

CIZ Stock Chart & Stats

GBX 1.15GBX 0.00(0.00%)

At close: Nov 04 4:30 PM GMT

Day’s Range: GBX 1.12 - GBX 1.20
52-Week Range: GBX 0.90 - GBX 3.90
Previous Close: GBX 1.15
Volume: N/A
Average Volume (3M): 1.33M
Market Cap: GBP 5.52M
Enterprise Value: GBP 10.43M
Total Cash (Recent Filing): GBP 81.00K
Total Debt (Recent Filing): GBP 0
Price to Earnings (P/E): ―
Beta: -0.93
Next Earnings: May 05, 2027 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Diagnostic Technology Focus

A clearly defined diagnostic focus gives the company a specific technology platform around which clinical validation, regulatory progress and commercialization can be organized. If the CIZ1B test advances successfully, the focused product strategy could support licensing or partnership-led expansion.

Low Reported Debt

Very low reported debt reduces fixed financial obligations and avoids the interest burden associated with significant leverage. This provides some structural protection while the company develops its technology, although it does not remove the need to fund ongoing research and operating losses.

Partner-led Commercialization Model

A partnership-led commercialization model could allow Cizzle to use established companies for manufacturing, marketing and distribution rather than building those capabilities internally. Upfront, milestone and royalty-based economics also provide a potential route to scale if validation and regulatory milestones are achieved.

Bears Say

Pre-commercial Revenue Profile

The absence of reported revenue means the business has not yet demonstrated recurring commercial demand or monetization of its diagnostic technology. Until commercialization begins, financial progress remains dependent on development milestones and access to external funding rather than operating income.

Persistent Operating Losses

Recurring operating losses show that current activities are not yet self-funding and that profitability depends on successful commercialization or other financing. The widening loss in 2025 also provides limited evidence that the underlying cost base is moving sustainably toward break-even.

Shrinking Capital Base

Negative equity and sharply reduced total assets indicate substantial erosion of the company’s capital base. This weakens financial flexibility, limits the resources available for development and increases dependence on future funding to sustain operations and pursue regulatory or commercial milestones.

Cizzle Biotechnology Holdings PLC News

Cizzle Biotechnology Gains Industry Recognition for Early Lung Cancer Test

Cizzle Biotechnology Holdings PLC ( ($GB:CIZ) ) has shared an announcement. Cizzle Biotechnology Holdings PLC, a UK-based developer of blood-based diagnostics for early cancer detection, is advancing commercialisation of its

2w agoCIZ E7F0

Cizzle Biotechnology Restructures U.S. Royalty Deal as Lung Cancer Test Rollout Accelerates

Cizzle Biotechnology Holdings PLC ( ($GB:CIZ) ) has provided an update. Cizzle Biotechnology has validated its CIZ1B lung cancer biomarker test in a CLIA-accredited U.S. laboratory and is expanding access

3w agoCIZ E7F0

Cizzle Biotechnology Enters Commercial Phase as U.S. Lung Cancer Test Wins CLIA Approval

Cizzle Biotechnology Holdings PLC ( ($GB:CIZ) ) has issued an update. Cizzle Biotechnology has transitioned from development to commercialisation after its CIZ1B biomarker blood test for early-stage lung cancer gained

1M agoCIZ E7F0

Cizzle expands U.S. lung cancer test access with new BioBridge lab deal

Cizzle Biotechnology Holdings PLC ( ($GB:CIZ) ) has provided an update. Cizzle Biotechnology’s North American licensee, Cizzle Bio Inc, has signed a strategic laboratory agreement with BioBridge Global’s BBG Advanced

3M agoCIZ E7F0

Cizzle Biotechnology’s Lung Cancer Blood Test Enters Full Commercial Sales in Key Texas Markets

The latest announcement is out from Cizzle Biotechnology Holdings PLC ( ($GB:CIZ) ). Cizzle Biotechnology’s North American partner Cizzle Bio Inc has begun full commercial sales of the CIZ1B biomarker

3M agoCIZ E7F0

Cizzle Biotechnology Enters Commercial Phase With U.S. Lung Cancer Test Accreditation

An announcement from Cizzle Biotechnology Holdings PLC ( ($GB:CIZ) ) is now available. Cizzle Biotechnology has entered a pivotal commercial phase after its CIZ1B blood test for early-stage lung cancer

3M agoCIZ E7F0

Cizzle Biotechnology Appoints Zeus Capital as Sole Corporate Broker

Cizzle Biotechnology Holdings PLC ( ($GB:CIZ) ) just unveiled an announcement. Cizzle Biotechnology Holdings plc is a life sciences company specialising in a proprietary CIZ1B biomarker blood test for the

4M agoCIZ E7F0

Cizzle Biotechnology shareholders back all AGM resolutions, expand board authorities

Cizzle Biotechnology Holdings PLC ( ($GB:CIZ) ) has issued an announcement. Cizzle Biotechnology Holdings reported that all resolutions at its latest annual general meeting were passed by a show of

4M agoCIZ E7F0

Cizzle wins U.S. CLIA approval for CIZ1B early lung cancer blood test

Cizzle Biotechnology Holdings PLC ( ($GB:CIZ) ) just unveiled an announcement. Cizzle Biotechnology has secured CLIA accreditation in the U.S. for its proprietary CIZ1B biomarker blood test, enabling clinical use

4M agoCIZ E7F0

Cizzle Biotechnology Gains Key U.S. Patent for CIZ1B Lung Cancer Test

An announcement from Cizzle Biotechnology Holdings PLC ( ($GB:CIZ) ) is now available. Cizzle Biotechnology has secured a key U.S. patent covering its core methods for measuring the CIZ1B lung

4M agoCIZ E7F0

CIZ FAQ

What was Cizzle Biotechnology Holdings PLC’s price range in the past 12 months?

Cizzle Biotechnology Holdings PLC lowest share price was 0.90 p and its highest was 3.90 p in the past 12 months.

What is Cizzle Biotechnology Holdings PLC’s market cap?

Cizzle Biotechnology Holdings PLC’s market cap is £5.52M.

When is Cizzle Biotechnology Holdings PLC’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Cizzle Biotechnology Holdings PLC’s earnings last quarter?

Cizzle Biotechnology Holdings PLC released its earnings results on Sep 30, 2026. The company reported -0.001 p earnings per share for the quarter.

Is Cizzle Biotechnology Holdings PLC overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Cizzle Biotechnology Holdings PLC pay dividends?

Cizzle Biotechnology Holdings PLC does not currently pay dividends.

What is Cizzle Biotechnology Holdings PLC’s EPS estimate?

Cizzle Biotechnology Holdings PLC’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cizzle Biotechnology Holdings PLC have?

Cizzle Biotechnology Holdings PLC has 480,320,340 shares outstanding.

What happened to Cizzle Biotechnology Holdings PLC’s price movement after its last earnings report?

Cizzle Biotechnology Holdings PLC reported an EPS of -0.001 p in its last earnings report. Following the earnings report the stock price went down -8.824%.

Which hedge fund is a major shareholder of Cizzle Biotechnology Holdings PLC?

Currently, no hedge funds are holding shares in GB:CIZ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description